China’s first GM rice gets US FDA approval
By Bai Tiantian,
Global Times
| 01. 22. 2018
A genetically modified (GM) rice product developed by a group of Chinese scientists has acquired the US Food and Drug Administration (FDA) approval, the first such Chinese product allowed to enter the US market.
However, neither China nor the US has approved mass cultivation of the rice amid low acceptance from the Chinese public for GM food.
Huahui No.1 rice, developed by the Huazhong Agricultural University, is genetically engineered to resist a wide range of insects, thus reducing the use of pesticides.
Lin Yongjun, a professor at Huazhong Agricultural University and one of the scientists that developed the rice, told the Global Times on Monday that Huahui No.1 could not be grown in China as "the country has not conducted regional trials nor provided guidelines to examine genetically engineered rice."
Lin said his team might consider growing Huahui No. 1 in Southeast Asian countries, "but our reach is limited and we hope the authorities can provide funding and legal support."
Lin's university received an email from the FDA on January 11 approving the rice.
The email, which was made public...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...